Abstract:
The invention relates to a method for preparing sulfanyl-type endothelin receptor antagonists of general formula (I) wherein R represents hydroxy, alkoxy, sulfonamidyl, amino; R represents alkyl, aryl or heteroaryl, optionally substituted, and R , R , R can be the same or different and are alkyl or aryl, optionally substituted, by means of nucleophilic reaction of a carboxylic acid derivative of formula (II) with a sulfide of formula (III), X being SR or SO2R and R being alkyl or aryl, optionally substituted.
Abstract:
Carboxylic acid derivatives have the formula (I), in which R1 stands for tetrazole or a group (a); R2 stands for hydrogen, hydroxy, NH¿2?, NH(C1-c4-alkyl), N(C1-C4-alkyl)2, halogen, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkinyl, C1-C4-halogenalkyl, C1-C4-alkoxy, C1-C4-halogenalkoxy or C1-C4-alkylthio, or CR?2¿ is linked with CR10, as indicated below, into a 5- or 6-membered ring; X stands for nitrogen or methine; Y stands for nitrogen or methine; Z stands for nitrogen or CR10, wherein R10 is hydrogen or C¿1?-C4-alkyl or CR?10¿ forms together with CR?2 or CR3¿ an optionally substituted 5- or 6-membered alkylene or alkenylene ring, and wherein one or more methylene groups can be substituted by oxygen, sulphur, -NH or -N(C¿1?-C4-alkyl); R?3¿ stands for hydrogen, hydroxy, NH¿2?, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, halogen, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkinyl, C1-C4-hydroxyalkyl, C1-C4-halogenalkyl, C1-C4-alkoxy, C1-C4-halogenalkoxy, C1-C4-alkylthio; or CR?3¿ is linked to CR10 as indicated above into a 5- or 6-membered ring, R?4 and R5¿ (which may be identical or different) stand for optionally substituted phenyl or naphthyl, or for phenyl or naphthyl which are linked to each other at the ortho-position by a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulphur atom or an SO¿2?, NH or N-alkyl group; optionally substituted C3-C8-cycloalkyl; R?6¿ stands for optionally substituted C¿3?-C8-cycloalkyl; optionally substituted phenyl or naphthyl, a 5- or 6-membered, optionally substituted heteroaromatic compound containing one to three nitrogen atoms and/or one sulphur or oxygen atom; W stands for sulphur or oxygen; Q is a spacer with a length that corresponds to a C2-C4 chain. Also disclosed are the physiologically tolerable salts of these compounds, as well as their pure enantiomer and diastereoisomer forms, their preparation and use as mixed ETA/ETB-receptor antagonists.
Abstract:
The invention relates to carboxylic acid derivatives of formula (I), wherein R represents a group (a) or (b), R and R being the same or different and having the following meaning: hydrogen; on the condition that R and R are not hydrogen at the same time, C1-C8-alkyl, C3-C8-cycloalkyl, C3-C8-alkenyl, C3-C8-alkinyl, benzyl, phenyl, naphthyl, optionally substituted; or R and R together form an optionally substituted C3-C7-alkylene chain which is closed in a ring and in which an alkylene group can be replaced by oxygen, sulphur or nitrogen; or R and R together form an optionally substituted C3-7-alkylene chain or C3-C7-alkenylene chain which is closed in a ring and to which an optionally substituted phenyl ring is anellated. The other substituents have the meanings given in the description. The invention also relates to the production of the novel carboxylic acid derivatives and to their use as endothelin receptor antagonists.
Abstract:
A carboxylic acid derivative or a physiologically tolerated salts or enantiomerically pure forms thereof has the formula (I) wherein: R is tetrazole or -C(O)-R1; R1 is OR7, cycloalkyl, alkyl, or optionally substituted CH2-phenyl, alkenyl, alkynyl or phenyl; R4 and R5 are independently optionally substituted phenyl or naphthoyl or phenyl or naphthyl which are linked together in the ortho positions by a direct linkage, methylene, ethylene or ethenylene, oxygen, sulphur, SO2, NH or N-alkyl; R6 is H, or optionally substituted alkyl, alkenyl, alkynyl, phenyl, naphthyl, a five or six membered heteroaromatic system comprising one to three nitrogens and/or sulphur or oxygen or cycloalkyl; Z is sulphur or oxygen; B is alkylene; Het is a heterocyclic radical of formula Ia or Ib'; R2 is H, OH, N(R')2, halo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, alkylthio or CR2 is linked to C10 to form a 5 or 6 membered ring defined below or if Het is a 5 membered ring, CR2 together with CR3 can be an optionally substituted 5- or 6- membered alkenyl or alkylenyl ring; X and Y are independently nitrogen or methane; W is nitrogen or CR10; R10 is H, halo or alkyl or CR10 forms together with CR2 or CR3 an optionally substituted 5 or 6 membered alkylene or alkenylene ring wherein one or more of the methylene groups can be replaced by oxygen, sulphur or NR'; R3 is H, OH, N(R')2, halo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, halolkoxy, alkylthio or CR3 is linked to C10 to form a 5 or 6 membered ring defined above; R' is H or alkyl; T is O, S or NR8 and R8 is alkyl. A pharmaceutical composition thereof is useful as an endothelin receptor antagonist.
Abstract:
The invention relates to new carboxylic acid derivatives of the formula (I), where the substituents have the meaning given in the description, their production and their use as endothelin-receptor antagonists.
Abstract:
Derivados de ácido carboxílico de la fórmula I En la que los sustituyentes tienen los significados siguientes:R1 tetrazol o un grupo Ra) un radical OR7 , donde R7 significa:hidrógeno, el catión de un metal alcalino, el catíón de un metal alcalinotérreo o un ión amonio fisiológicamente tolerado;C3-C8-cicloalquilo, C1-C8-alquilo,CH2-fenilo eventualmente sustituido,Un grupo C3-C6-alquenilo o un grupo C3-C6-alquinilo eventualmente sustituido, o fenilo eventualmente sustituido. un heteroátomo de 5 miembros ligado por vía de un átomo de nitrógenoun grupo Donde k puede adoptar los valores 0,1 y 2, p los valores 1, 2, 3 y 4 y R8 significaC1-C4-alquilo, C3-C8-cicloalquilo, C3-C6-alquinilo o fenilo eventualmente sustituido.d) un radical Donde R9 significa:C1-C4-alquilo, C3-C6-alquinilo, C3-C8-cicloalquilo, C1-C4-halógenoalquilo, pudiendo estos radicales llevar un radical C1-C4-alcoxi, C1-C4-alquiltio y/o un radical fenilo;- 2 -e) un grupo Pudiendo R13 y R14 ser idénticos o diferentes y tener los significados siguientes:Hidrógeno, C1-C8-alquilo, C3-C8-cicloalquilo, C3-C8-alquenilo,C3-C8-alquinilo, bencilo, fenilo, eventualmente sustituidoO R13 y R14 forman juntos una cadena de C4-C7-alquileno cerrada formando un anillo, eventualmente sustituida, y que puede contener un heteroátomo, oR2 hidrógeno, hidroxi, NH2, NH(C1-C4-alquilo), N(C1-C4-alquilo)2, halógeno, C1-C4-alquilo C2-C4-alquenilo, C2-C4-alquinilo, C1-C4-hidroxialquilo, C1-C4-halógenoalquilo, C1-C4-alcoxi, C1-C4-halógenoalcoxi o C1-C4-alquiltio, o CR2 está ligado con CR10 en la forma abajo indicada, formando un anillo de 5 ó 6 miembros. a X nitrógeno o metino.Y nitrógeno o metino.Z nitrógeno o CR10, significado R10 hidrógeno, hidroxi, C1-C4 -halógenoalquilo o C1-C4-alquilo, o CR10 forma junto con CR2 o CR3 un anillo de alquileno o alquenileno de 5 ó 6 miembros, que puede estar eventualmente sustituido, y donde cada vez uno o varios grupos metileno pueden estar sustituidos por oxígeno, azufre, -NH o N(C1-C4-alquilo)2 .R3 hidrógeno, hidroxi, NH2, NH(C1-C4-alquilo), N(C1-C4-alquilo)2, halógeno, C1-C4-alquilo, C2-C4-alquenilo, C2-C4-alquinilo, C1-C4-halógenoalquilo, C1-C4-alcoxi, C1-C4-halógenoalcoxi, C1-C4-hidroxialquilo, C1-C4-alquiltio, o CR3 está ligado con CR10, en la forma arriba indicada, formando un anillo de cinco o seis miembros.R4 C1-C4-alquilo, C2-C4-alquenilo o C2-C4-alquinilo, eventualmente sustituidoR5 fenilo o naftilo, eventualmente sustituido, o fenilo o naftilo, que está ligado en la posición orto por vía de un enlace directo, un grupo metileno, etileno o etenileno, un átomo de oxígeno o de azufre o un grupo SO2 , NH o N-alquilo con R4 C3-C8-cicloalquilo eventualmente sustituido;R6 C3-C8-cicloalquilo eventualmente sustituido; fenilo o naftilo, que en cada caso pueden llevar uno o varios de los radicales siguientes; halógeno, R15, nitro, mercapto, carboxi, ciano, hidroxi, amino, C1-C4-alquilo, C2-C4-alquenilo, C2-C4-alquinilo, C3-C6-alqueniloxi, C1-C4-halógenoalquilo, C3-C6-alquiniloxi, C1-C4-alquilcarbonilo, C1-C4-alcoxicarbonilo, C1-C4-alcoxi, C1-C4-halógenoalcoxi, fenoxi, C1-C4-alquiltio, NH(C1-C4-alquilo), N(C1-C4-alquilo)2, dioxometileno, dioxoetileno o fenilo, que puede estar mono o polisustituido, P.ej. mono a trisustituido por halógeno, nitro ciano, C1-C4-alquilo, C1-C4-halógenoalquilo, C1-C4-alcoxi, C1-C4-halógenoalcoxi o C1-C4-alquiltio, siendo preciso, que cuando R6 es un radical fenilo sin sustituir, entonces R2 y R3 no pueden significar simultáneamente OCH3;un heteroaromático de cinco o seis miembros, que contiene de uno a tres átomos de nitrógeno y/o un átomo de azufre o de oxígeno, que puede llevar uno a cuatro átomos de halógeno y/o uno de los radicales siguiente:C1-C4-alquilo, C2-C4-alquenilo, C1-C4-halógenoalquilo, C1-C4-alcoxi, C1-C4-halógenoalcoxi, C1-C4-alquiltio, fenilo o fenoxi, pudiendo los radicales fenilo a su vez llevar uno de cinco átomos de halógeno y/o uno a tres de los radicales siguientes: C1-C4-alquilo, C1-C4-halógenoalquilo, C1-C4-alcoxi, C1-C4-halógenoalcoxi y/o C1-C4-alquiltio;R15 C1-C4-alquilo, C1-C4-alquiltio, C1-C4-alcoxi, que llevan uno de los radicales siguientes hidroxi, carboxi, amino, NH(C1-C4-alquilo), N(C1-C4-alquilo)2, carboxamida o CON(C1 -C4-alquilo)2,W azufre u oxígeno;Q un espaciador, que en su longitud equivale a una cadena de 2 a 4 átomos de carbono,Así como sus sales fisiológicamente toleradas, y las formas enantiómeras y diastereómeras.
Abstract:
The invention relates to carboxylic acid derivatives of formula (I), wherein the substituents have the following meanings; R = tetrazole or a group (1); R = a radical OR (2), (3), a 5-membe red heteroaromatic bonded by a nitrogen atom such a pyrrolyl, pyrazolyl, imidazolyl and trizolyl; R , R = hydrogen, hydroxy, NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, halogen, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkinyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-halogen alkyl, C1-C4-alkoxy, C1-C4-halogen alkoxy or C1-C4-alkythio; X = halogen, C1-C4-halogen alkyl, hydroxy; R and R = phenyl or naphthyl, C3-C7-cycloalkyl, phenyl or naphthyl which are bonded in ortho position by a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an SO2-NH or an N-alkyl group or a 5-membered or 6-membered heteroaromatic; R = hydrogen, phenyl or naphthyl, a five or six-membered heteroaromatic, C1-C8-alkyl, C3-C6-alkenyl, C3-C6-alkinyl or C3-C8-cycloalkyl, whereby said radicals can be substituted once or many times, with the proviso that R can only stand for hydrogen if Z does not represent a single bond; Z = sulfur, oxygen or a single bond, in addition to the physiologically compatible salts and the enantiomeric-pure and diastereomeric-pure forms. The novel compounds are suitable for combating diseases, especially as endothelin antagonists.
Abstract:
The invention relates to carboxylic acid derivatives of formula (I), in which the substituents have the following meanings: R is tetrazol or a group (a); W and Z, can be identical or different and are nitrogen or methine, provided that if W and Z are methine, then Q is nitrogen; X is nitrogen or CR ; Y is nitrogen or CR ; Q is nitrogen or CR , provided that if Q is nitrogen then X is CR and Y is CR ; R and R are identical or different and are possibly substituted phenyl or naphthyl or phenyl or naphthyl which are linked in an ortho position via a direct bond, a methlyene, ethylene or ethenylene group, an oxygen or sulfur atom or a SO2-, NH- or N-alkyl group or possibly substituted C5-C6-cycloalkyl; R is a rest (b) or (c); and R is hydrogen, C1-C4-alkyl. The invention further relates to their preparation and their use as endothelin receptor antagonists. The invention also relates to compounds of formula (II) and a structural fragment of formula (d) in which the rests R , R , R , R and R have the meanings given in claim no. 1 and to their use as structural elements in an endothelin receptor antagonist.
Abstract:
The invention relates to carboxylic acid derivatives of formula (I), wherein the substituents have the following meanings; R = tetrazole or a group (1); R = a radical OR (2), (3), a 5-membe red heteroaromatic bonded by a nitrogen atom such a pyrrolyl, pyrazolyl, imidazolyl and trizolyl; R , R = hydrogen, hydroxy, NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, halogen, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkinyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-halogen alkyl, C1-C4-alkoxy, C1-C4-halogen alkoxy or C1-C4-alkythio; X = halogen, C1-C4-halogen alkyl, hydroxy; R and R = phenyl or naphthyl, C3-C7-cycloalkyl, phenyl or naphthyl which are bonded in ortho position by a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an SO2-NH or an N-alkyl group or a 5-membered or 6-membered heteroaromatic; R = hydrogen, phenyl or naphthyl, a five or six-membered heteroaromatic, C1-C8-alkyl, C3-C6-alkenyl, C3-C6-alkinyl or C3-C8-cycloalkyl, whereby said radicals can be substituted once or many times, with the proviso that R can only stand for hydrogen if Z does not represent a single bond; Z = sulfur, oxygen or a single bond, in addition to the physiologically compatible salts and the enantiomeric-pure and diastereomeric-pure forms. The novel compounds are suitable for combating diseases, especially as endothelin antagonists.